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By deﬁnition, nongonococcal urethritis (NGU) is an infectious condition involving urethra inﬂammation
without Neisseria gonorrhoeae infection. According to recent studies, NGU accounts for 10e30% of initial
visits to sexually transmitted infection (STI) clinics, and is one of the most common forms of STI in men.
Chlamydia trachomatis is the most prevalent and well-established pathogen in NGU. However, non-
chlamydial NGU is still a problematic disease in clinics because of its minimally symptomatic or
asymptomatic manifestation. Various infection causes, including Mycoplasma, Trichomonas vaginalis, and
herpes simplex virus, are possible pathogens in nonchlamydial NGU. In this brief review, we focus on the
evaluation and management of nonchlamydial NGU.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.1. Introduction
According to the National Health Insurance Database in
Taiwan, the prevalence of sexually transmitted infection (STI) has
been gradually rising in the past decades. Neisseria gonorrhoeae
and Chlamydia urethritis are the most common pathogens of STIs
in men. Nongonococcal urethritis (NGU), characterized by a
urethral inﬂammation that is not caused by N. gonorrhoeae
infection, is probably the most common form of STI in men. It
accounts for 10e30% of new male cases in STI clinics.1 Many
pathogens can be identiﬁed for NGU and Chlamydia trachomatis is
the most prevalent and well-established. C. trachomatis infection
accounts for 15e40% of cases of initial NGU, and some studies
have reported up to 50% of new cases.1,2 However, nonchlamydial
NGU is still a problematic disease for clinics. Various infectious
pathogens, including Mycoplasma, viruses, and protozoan para-
sites, are possible causes of NGU3 and exhibit similar symptoms.
However, pathogens still cannot be detected in most cases of
nonchlamydial NGU.2,4,5 This makes it difﬁcult for physicians to
make an accurate diagnosis.
In this brief review, we focus on the common pathogens of
nonchlamydial NGU: their prevalence, evaluation, and pathogen-
esis. The recommended regimens and prevention strategies for
various causes of nonchlamydial NGU are also discussed in this
article.aohsiung Municipal Ta-Tung
strict, Kaohsiung City 80145,
-C. Tsai).
ciation. Published by Elsevier Taiw2. Urethritis
Urethritis, which is characterized by urethral inﬂammation,
results from infectious, traumatic, and immune sources. In the in-
fectious case, urethritis is usually acquired through an STI and
shows similar symptoms and signs. In general, mucopurulent or
purulent discharge from the urethral meatus and dysuria are the
most common presentations (Fig. 1). An itching or burning sensa-
tion in the urethra is also typical. It is diagnosed according to the
mentioned ﬁndings or one of the following laboratory tests.4 (1)
The diagnosis is positive if a Gram stain of urethral discharge shows
more >5 white blood cells (WBCs) per oil-immersion ﬁeld. This
recommended microscopic test is rapid, and features high sensi-
tivity and speciﬁcity to identify a gonorrheal infection. (2) The
diagnosis is positive if a microscopic examination of ﬁrst-void urine
shows>10WBCs per high-power ﬁeld. (3) The diagnosis is positive
if a leukocyte esterase test of ﬁrst-void urine shows positive results.
Using a urethral swab to collect secretions for cultures, hybrid-
ization tests, or nucleic acid ampliﬁcation tests (NAATs) is a com-
mon diagnostic method to conﬁrm a pathogen, whereas ﬁrst-void
urine specimens can only be tested using NAATs. Recently, NAATs
have become gradually accepted and preferred for conﬁrmation of
the pathogen of infectious urethritis because of their high sensi-
tivity and speciﬁcity. If diagnostic tools and microscopic tests are
unavailable, the Center for Disease Control and Prevention (CDC)
recommends that sexually active patients who present with ure-
thritis upon examination be treated with drug regimens effective
against both gonorrhea and chlamydiasis.4 Despite the availability
of numerous testing methods, a pathogen still cannot be detected
in many cases of urethritis, especially in nonchlamydial NGU.
Numerous cases of nonchlamydial NGU go unnoticed because ofan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Nonchlamydial nongonococcal urethritis presents with mucopurulent dis-
charges from the urethral meatus.
Fig. 2. Light microscopic picture of Trichomonas vaginalis in smear.
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Although the prevalence of nonchlamydial NGU is not uniform
among communities and populations, it is usually highest in ado-
lescents and adults <25 years old.
It is estimated that 10e20% of chlamydial NGU and 20e30% of
nonchlamydial NGU may be recurrent within 6 weeks after
symptomatic resolution.1 Incorrect diagnosis, combined STIs,
incomplete therapeutic regimens, and reinfection by an infected
sexual partner are the major causes of recurrent or persistent NGU.
To minimize transmission, a complete course of treatment should
be initiated immediately after diagnostic conﬁrmation. Men with
documented NGU have a high rate of reinfection within 6 months
after treatment, therefore, repeat testing of all men diagnosed with
NGU is recommended 3e6 months after treatment.6,7 Additionally,
because asymptomatic infection is common and the risk of co-
infection is high, partners of men with initial NGU should be
evaluated and considered for treatment. The CDC suggests that all
sexual partners within the preceding 60 days be referred for eval-
uation, testing, and empirical treatment with a drug regimen
effective against Chlamydia. To eliminate the risk of reinfection,
men treated for NGU should also be asked to refrain from sexual
behavior for at least 7 days after symptomatic resolution and
complete a therapeutic regimen.4 STIs are important cofactors in
HIV transmission, thus, it is also recommended that patients who
have been diagnosed with initial NGU receive testing for other STIs,
especially human immunodeﬁciency virus (HIV) infection and
syphilis.
3. Mycoplasma
Mycoplasma, a type of Gram-negative bacteria without a cell
wall, represents several original species. Among several recognized
species of genital mycoplasmas, Mycoplasma genitalium, Ure-
aplasma spp., and Mycoplasma hominis, are believed to be possible
pathogens in the genitourinary tract of humans. However, only
M. genitalium and Ureaplasma urealyticum have been recognized as
possible etiological agents of NGU.Mycoplasma genitalium infection
is the most frequently reported pathogen in nonchlamydial NGU.
Approximately 15e25% of cases of NGU are thought to be caused by
M. genitalium.2 Previous studies8,9 have demonstrated a strong
association between M. genitalium infection and NGU in men,
especially among those with recurrent or persistent NGU. In
contrast to the positive correlation of M. genitalium to NGU,
U. urealyticum is relatively uncommon and weakly associated withmost NGU patients. Recent data supporting U. urealyticum as a
commensal or pathogenic bacterium are inconsistent.2,3,5 Further
studies are required to improve our understanding of the role of
U. urealyticum in NGU.
In a clinical manifestation of NGU, the urethral discharge
is usually clear or mucoid, and has >5 WBCs per oil-immersion
ﬁeld. Although M. genitalium infection of NGU usually induces
symptoms of urethral inﬂammation, asymptomatic infection is still
common. The typical diagnostic methods used to detect
M. genitalium urethritis are culture or direct microscopic smear.
However, these two methods have relatively low sensitivity. A
culture test requires swab specimens from the urethra.
M. genitalium is more difﬁcult to culture than other species of
Mycoplasma, therefore, cultures have little beneﬁt in clinical
diagnosis. In recent clinical practice,M. genitalium-related NGU has
been detected with NAATs by testing ﬁrst-void urine or collecting
urethral discharges.10 Mycoplasma spp. have no cell wall, thus,
M. genitalium is resistant to all b-lactams or cephalosporins. The
recommended antibiotics for M. genitalium-related NGU are
macrolides (such as azithromycin) or tetracyclines (such as
doxycycline). The dose regimens are the same as for chlamydial
infection, and treatment should start after diagnosis. Some studies
have reported that a single 1-g dose of azithromycin is more
effective than doxycycline.4,11 However, treatment using these two
antibiotics fails in some cases of chronic NGU caused by inadequate
treatment and recurrent infection.9,12
4. Trichomoniasis
Trichomoniasis is caused by Trichomonas vaginalis and is the
most prevalent nonviral STI in sexually active populations, and af-
fects an estimated 170 million people worldwide.13,14 Trichomoni-
asis, which is primarily observed in women, presents as an
asymptomatic manifestation in up to one-third of infected women.
Symptomatic manifestations involve inﬂammation, an itching
sensation around the genital area, vulvar irritation and erythema,
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typical erythematous cervix with punctate areas of exudation, also
known as a strawberry cervix. However, the prevalence of the
T. vaginalis infection in men is not well known because most
infected men have minimal or no symptoms and transmit the
pathogen unknowingly.15 In a recent study, 75% of infected men
were asymptomatic.16 Other screenings of the community showed
that the prevalence of trichomoniasis in men is approximately
10%17 in nonclinical cases and 12e17% in STI clinical cases.18e20
Other infected male patients may have symptoms similar to those
of other NGUs. T. vaginalis has been recognized as a cause of non-
chlamydial NGU in men, in whom it has the potential to induce
balanoposthitis, epididymitis, urethral stricture, prostatitis, infer-
tility, and even prostate cancer.21e25Fig. 3. The algorithm for the management of nonchlamydial nongonococcal urethritis in
ampliﬁcation tests; PCR ¼ polymerase chain reaction.Various diagnostic methods are used to detect T. vaginalis-
related NGU. Typically, diagnosis of trichomoniasis in men is
conﬁrmed by direct microscopic examination of secretions from all
genitourinary sites, such as the urethra, epididymis, prostate, and
semen (Fig. 2). However, this method has relatively low sensitivity,
and is impractical in clinical and nonclinical settings.4 Culture
testing of a urethral swab, ﬁrst-void urine, or semen is another
highly speciﬁc option. However, it is still not a sensitive diagnostic
method. Urethral cultures are able to grow T. vaginalis in only 60% of
cases.25 However, recent polymerase chain reactions and rapid
antigen tests for the detection of T. vaginalis from ﬁrst-void urine or
urethral swabs have superior sensitivity for T. vaginalis diagnosis in
men, and have become increasingly popular.18,26e28 A single 2-g
dose of metronidazole or tinidazole, taken orally, is the regimenmen. HSV ¼ herpes simplex virus; IgG ¼ immunoglobulin G; NAAT ¼ nucleic acid
C.-C. Tsai, C.-C. Li / Urological Science 24 (2013) 73e7776recommended by the CDC for T. vaginalis infection, or recurrent
NGU, in men. The alternative regimen is 500 mg metronidazole
taken orally twice a day for 7 days.4 Patients should avoid drinking
alcohol during treatment, and for at least 24 hours after completion
of metronidazole or 72 hours after completion of tinidazole, to
prevent a disulﬁram-like reaction.
This infection is typically acquired during sexual intercourse,
and other circumstances of contamination are rare. Even without
symptoms, an asymptomatic carrier continues to infect or reinfect a
sexual partner until he or she has been treated. In a previous study,
T. vaginalis was isolated from 67e100% of female partners of
infected men and 14e60% of male partners of infected women.29 A
more recent study also indicated that 73% of male sexual partners
of women who had trichomoniasis were positive for T. vaginalis
infection.16 Another community-based study showed that the
prevalence of trichomoniasis was 10.7% in women and 6.3% in their
male partners.30 Therefore, we suggest a concomitant survey and, if
necessary, treatment of sexual partners of the infected person
when the diagnosis of T. vaginalis infection is conﬁrmed.
5. Herpes simplex virus
Herpes simplex virus (HSV) is an important pathogen in genital
and oral isolates and is separated into two types. Both HSV-1 and
HSV-2 have been recognized as causes of chronic, life-long genital
infections. HSV-2 infection has been identiﬁed as the dominant
cause of most recurrent genital ulcers. However, most people
infected with HSV-2 are asymptomatic and have not been diag-
nosed with genital herpes. It is a major problem that many of these
people tend to be unaware of their infection, and transmit the
infection to their sexual partners.
However, in populations with a high frequency of orogenital
exposure and anal intercourse, an increasing proportion of ano-
genital HSV-1 infection has been noted. Up to 50% of primary
genital herpes is caused byHSV-1, but its recurrence and subclinical
shedding are much less frequent than for genital HSV-2 in-
fections.4,5,31 The typical clinical manifestation of a genital HSV
infection is painful genital, anal, or perianal vesicles and ulcers, but
many genital HSV infections are still subclinical. HSV is also a re-
ported pathogen of NGU. Genital itching, dysuria, vaginal or ure-
thral discharge, and tender inguinal lymphadenopathy are other
predominant local symptoms of HSV infection. Urethral discharge
and dysuria, which are similar to the classical symptoms of NGU,
are noted in approximately one-third of men with a primary HSV
infection.5 Bradshaw et al2 have indicated that HSV, usually HSV-1,
accounts for 2e5% of cases of NGU. Consequently, sexually active
patients and sexual partners with genital herpes or mucocutaneous
lesions should be tested for HSV infection when NGU is diagnosed.
Virological tests, identiﬁcation of HSV from ﬁrst-void urine or
urethral swab using a cell culture or NAAT, are more reliable than a
physical examination, but are not widely available. Type-speciﬁc
serological assays for immunoglobulin G antibodies of HSV,
which determine the virus type, are more useful in clinical settings
to survey latent-virus infection. Conversely, immunoglobulin M
serological tests are not suggested as a diagnostic method because
of long-term persistence in chronic herpes, the frequency of false
results, and non-type-speciﬁc assays. Unlike recurrent genital HSV,
which is usually self-limited, all primary genital herpes-related
NGUs should be treated with recommended regimens of
acyclovir, famciclovir, or valacyclovir, in addition to azithromycin or
doxycyclin.1,4 The regimens recommended by the CDC are: 400 mg
acyclovir taken orally three times daily for 7e10 days, or 200 mg
acyclovir taken orally ﬁve times daily for 7e10 days; 250 mg fam-
ciclovir taken orally three times daily for 7e10 days, or 1 g vala-
cyclovir taken orally twice daily for 7e10 days. Systemic antiviraldrugs, which are capable of controlling the symptoms and reducing
the duration of herpes episodes, offer clinical beneﬁts to most
symptomatic patients. However, these drugs cannot destroy latent
viruses. To reduce recurrence of HSV, suppressive therapy for
recurrent genital herpes has been established. Suppressive antiviral
therapy has been reported to reduce the frequency of genital her-
pes recurrences by 70e80%.4,32 Topical therapies with antiviral
drugs have minimal and limited beneﬁts.
6. Conclusion
Asymptomatic infections are common and many patients are
treated without diagnostic conﬁrmation. Therefore, the prevalence
of nonchlamydial NGU is likely to be much higher than reported. In
clinical practice, it is a major problem that accurate diagnoses or
adequate solutions are usually absent in most cases of non-
chlamydial NGU. M. genitalium is the most common pathogen and
causes 15e25% of nonchlamydial NGU. Recurrent and persistent
nonchlamydial NGU should be evaluated for drug compliance and
uncommon infection, such as T. vaginalis, U. urealyticum, or HSV
infection. All persons with nonchlamydial NGU should remain
abstinent from sexual activity for at least 7 days after complete
treatment and symptomatic resolution. Comprehensive surveys of
other STIs, especially HIV infection, syphilis, and gonorrhea, are
recommended in the general treatment of nonchlamydial NGU
because the infections are commonly combined. Finally, this paper
describes clinical strategies in the management of nonchlamydial
NGU in men (Fig. 3).
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